A Real-world, Retrospective Observational Study of Targeted Therapy in Metastatic Colorectal Cancer
Not Applicable
Completed
- Conditions
- Health Condition 1: C260- Malignant neoplasm of intestinal tract, part unspecified
- Registration Number
- CTRI/2023/09/057410
- Lead Sponsor
- Dr. Reddy’s Laboratories Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
Male and female patients, = 18 years of age
Histologically confirmed diagnosis of mCRC
Patients who received bevacizumab, cetuximab, or panitumumab targeted therapies for the medical management of their disease in the first-line setting
Exclusion Criteria
Patients with follow-up data less than 6 months post-initiation of targeted therapies
Patients whose treatment with targeted therapy began before 2015 or more recently than 30 days prior to the ethics committee approval
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method